TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31577772

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavioral Therapy (REBT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 116
Study: 27836862

Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m2) for 5 days prior to EOX chemotherapy (E: 50 mg/m2, O: 130 mg/m2, X: 625 mg/m2 twice daily for 21 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m2) for 3 days prior to EOX chemotherapy
Number of subjects: 12
Study: 25801556

Group type: EXPERIMENTAL
Intervention: Colistin plus ascorbic acid (2 g every 12 h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Colistin plus ascorbic acid
Number of subjects: 28
Study: 23652808

Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 610
Study: 21865979

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (5 mL daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sunflower oil (SO) supplementation (5 mL daily)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 132
Study: 19625243

Group type: EXPERIMENTAL
Intervention: Glipizide XL, 10 mg orally daily (G group)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Glipizide XL, 10 mg orally daily, plus insulin glargine, 10 U daily (G+G group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Both treatment groups (G and G+G)
Number of subjects: 77
Study: 17346444

Group type: EXPERIMENTAL
Intervention: 1% PLA2 inhibitor-containing cream
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16980850

Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Number of subjects: 4296

Group type: EXPERIMENTAL
Intervention: Scar ranking
Number of subjects: 4296
Study: 14610134

Group type: EXPERIMENTAL
Intervention: Treatment for spontaneous intracranial hypotension (exact treatment not specified)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group of sex- and age-matched neurology inpatients with normal CSF pressure
Number of subjects: 13
Study: 10474118

Group type: EXPERIMENTAL
Intervention: GH therapy (daily s.c. injections at a weekly dose of 8.2 mg/m(2) for 1.9-7.5 years)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 49
Study: 9102589

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 1 ml (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% bupivacaine 0.5 ml (group B)
Number of subjects: 100
Study: 1654739

Group type: EXPERIMENTAL
Intervention: Oat bran (OB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wheat bran (WB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 6352655

Group type: EXPERIMENTAL
Intervention: 0.25 g ceftazidime twice daily for five days
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 0.50 g ceftazidime twice daily for five days
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 1.00 g ceftazidime twice daily for five days
Number of subjects: 166
Study: 31926918

Group type: EXPERIMENTAL
Intervention: Berberine 0.3 g twice daily
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study: 30670262

Group type: EXPERIMENTAL
Intervention: Almond oil (10 ml, two times daily for 30 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study: 28629665

Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy (5 mg twice daily)
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Tofacitinib plus methotrexate (5 mg twice daily)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Adalimumab plus methotrexate (40 mg every other week)
Number of subjects: 1146
Study: 26004087

Group type: EXPERIMENTAL
Intervention: Amrubicin (40mg/m², days 1-3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Re-challenge with platinum doublet
Number of subjects: 60
Study: 23090719

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 40
Study: 21735192

Group type: EXPERIMENTAL
Intervention: 5 mg/day Letrozole (group 1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day Letrozole (group 2)
Number of subjects: 67
Study: 19370533

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (1, 2, or 3 cycles)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (2 cycles)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (3 cycles)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy
Number of subjects: 69
Study: 16510768

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 250 mg twice daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15585154

Group type: EXPERIMENTAL
Intervention: Absorption (AP) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hemodialysis (HD) group
Number of subjects: 90
Study: 11214094

Group type: EXPERIMENTAL
Intervention: Weekly chloroquine prophylaxis
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Daily iron and weekly folic-acid supplementation
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Case management of malaria
Number of subjects: 473

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 473
Study: 9323688

Group type: EXPERIMENTAL
Intervention: FOSL-HN (fish oil/medium-chain triglyceride structured lipid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: O-HN (isonitrogenous, isocaloric formula)
Number of subjects: 20
Study: 8498495

Group type: EXPERIMENTAL
Intervention: High sodium diet (200 meq/day)
Number of subjects: 8
Study: 2931096

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29391265

Group type: EXPERIMENTAL
Intervention: G‐CSF group (n = 18)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination group (G‐CSF + NAC) (n = 19)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard medical therapy group (n = 20)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: G‐CSF group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 57
Study: 26926657

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention (test 1 and test 2 groups)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (care from physician/nurses)
Number of subjects: 162
Study: 26277873

Group type: EXPERIMENTAL
Intervention: 3-in-1 block
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FI compartment block
Number of subjects: 10
Study: 23665196

Group type: EXPERIMENTAL
Intervention: Neurofeedback (40 theta/beta training sessions)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard pharmacological intervention (methylphenidate)
Number of subjects: 23
Study: 20662342

Group type: EXPERIMENTAL
Intervention: Nutritional program (NUT) - 10 mg/day iron, 11 mg zinc three times a week, 10000 IU/week of vitamin A
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) - 1.26 IU/kg/day (0.042 mg/kg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Passive observation (OBS)
Number of subjects: 54
Study: 18166090

Group type: EXPERIMENTAL
Intervention: Combination therapy (SRP + HMT + TAT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 171
Study: 16733739

Group type: EXPERIMENTAL
Intervention: 20 mg ferrous iron (fumarate)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 40 mg ferrous iron (fumarate)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 60 mg ferrous iron (fumarate)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 80 mg ferrous iron (fumarate)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (ferritin >70 microg/l)
Number of subjects: 301
Study: 12628113

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Temperature
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Leucocyte count
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Percentage of neutrophils
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Respiratory rate
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Sex (male)
Number of subjects: 430
Study: 12810974

Group type: EXPERIMENTAL
Intervention: Long segment Cotrel-Dubousset instrumentation (Group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Short segment Cotrel-Dubousset instrumentation (Group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neurological recovery in incomplete paraplegics
Number of subjects: 42
Study: 10586336

Group type: EXPERIMENTAL
Intervention: CHVP plus interferon (12 cycles in 18 months, interferon 5 MU TIW for 18 months)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Fludarabine alone (25 mg/m2/d x 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months)
Number of subjects: 131
Study: 8596381

Group type: EXPERIMENTAL
Intervention: Folic acid supplement (400 microgram/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Folic-acid-fortified foods (an additional 400 microgram/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dietary folate (an additional 400 microgram/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (V)
Number of subjects: 62
Study: 1947364

Group type: EXPERIMENTAL
Intervention: Cholinergic blockade with 30 micrograms kg‐1 atropine administered by intravenous injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6357772

Group type: EXPERIMENTAL
Intervention: progabide (+/- 30 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: progabide
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31976819

Group type: EXPERIMENTAL
Intervention: Physical therapy home program (4 visits) during chemotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: General exercise during chemotherapy
Number of subjects: 48
Study: 30816632

Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 2629

Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 2629

Group type: COMPARATOR
Intervention: Implant
Number of subjects: 2629

Group type: COMPARATOR
Intervention: Norethisterone enanthate
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: All contraceptive methods
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2629
Study: 28259141

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 76

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 76
Study: 26983164

Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Opiates
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Gabapentin/pregabalin
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Self-reported prescribing of acetaminophen/paracetamol and opiates
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Self-reported prescribing of gabapentin
Number of subjects: 173
Study: 25867579

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily for eight weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clarithromycin-surgery group
Number of subjects: 80
Study: 22119995

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fatigue (assessed via PWB item)
Number of subjects: 0
Study: 20629136

Group type: EXPERIMENTAL
Intervention: 20 mg/day istradefylline
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: 40 mg/day istradefylline
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 17049679

Group type: EXPERIMENTAL
Intervention: NefTat and gp120(W61D) recombinant vaccine with AS02A adjuvant
Number of subjects: 84
Study: 16296364

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with amino acid infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with amino acid infusion
Number of subjects: 30
Study: 11979398

Group type: COMPARATOR
Intervention: Pramlintide (25 microg/h or 50 microg/h) administered via 5-hour intravenous infusion
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pramlintide (30, 100, or 300 microg) administered via subcutaneous injections 3 times daily
Number of subjects: 102
Study: 9832919

Group type: EXPERIMENTAL
Intervention: Nurse-managed follow-up program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 7851967

Group type: EXPERIMENTAL
Intervention: PCR test for Mycobacterium tuberculosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control specimens (non-tuberculosis)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PCR test compared with Ziehl Neelsen staining and culture test
Number of subjects: 50
Study: 2697448

Group type: EXPERIMENTAL
Intervention: Urotel postal urine cytology kit
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard cytological method
Number of subjects: 184
Study: 11859

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY), 50 mg/kg on each of 4 successive days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Procarbazine-antithymocyte globulin-CY
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Second transplants attempted with original marrow donor or another HLA-identical sibling
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Marrow transplantation
Number of subjects: 49
Study: 29241082

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Working Memory Training (WM-training)
Number of subjects: 24
Study: 28318450

Group type: EXPERIMENTAL
Intervention: Fasting session (FS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control session (CS)
Number of subjects: 21
Study: 25741644

Group type: EXPERIMENTAL
Intervention: Acupressure at the SP6 point for 20 min during contractions
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control
Number of subjects: 156

Group type: COMPARATOR
Intervention: Acupressure, Placebo, Control
Number of subjects: 156
Study: 21564310

Group type: EXPERIMENTAL
Intervention: Elite swimmers with shoulder pain
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elite swimmers without shoulder pain
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matched controls (healthy athletes)
Number of subjects: 50
Study: 21068679

Group type: COMPARATOR
Intervention: Cold without warm-up
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cold with warm-up
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ambient temperature without warm-up (AMB)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ambient temperature with warm-up (AMBWU)
Number of subjects: 9
Study: 19010165

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17079539

Group type: EXPERIMENTAL
Intervention: Proximity to neighborhood and community parks
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Presence of parks within a half-mile radius
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Presence of parks beyond a half-mile radius
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Access to specific park amenities (walking paths, running tracks, playgrounds, basketball courts)
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Miniparks, natural resource areas, walking paths, running tracks within a half-mile
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Parks with streetlights and floodlights
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Overall presence of parks
Number of subjects: 1556

Group type: EXPERIMENTAL
Intervention: Using the 3.0 metabolic equivalent cutpoint
Number of subjects: 1556
Study: 14628394

Group type: EXPERIMENTAL
Intervention: Advanced cardiac life support (ACLS) recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intervention via cardiopulmonary resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awareness of patients' wishes regarding CPR initiation
Number of subjects: 0
Study: 11559337

Group type: EXPERIMENTAL
Intervention: Rigid nasendoscope
Number of subjects: 56
Study: 9288839

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 72 Gy/45 fractions/5 weeks
Number of subjects: 512

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 70 Gy/35 fractions/7 weeks
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 512
Study: 8298936

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 137
Study: 3571741

Group type: EXPERIMENTAL
Intervention: Self-control therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Behavioral problem-solving therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 29
Study: 2653297

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 50

Group type: COMPARATOR
Intervention: outpatient myelography
Number of subjects: 50

Group type: COMPARATOR
Intervention: inpatient myelography
Number of subjects: 50
Study: 31689780

Group type: EXPERIMENTAL
Intervention: Social support interventions (16 sessions over 8 weeks, 2 times a week)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study: 28844201

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6006

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 6006
Study: 26279339

Group type: EXPERIMENTAL
Intervention: CYD-TDV (phase III lot 1)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: CYD-TDV (phase III lot 2)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: CYD-TDV (phase III lot 3)
Number of subjects: 712

Group type: COMPARATOR
Intervention: CYD-TDV (phase II lot)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study: 23886205

Group type: EXPERIMENTAL
Intervention: Aromatherapy with light Thai massage (3 sessions with ginger and coconut oil over 1 week)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aromatherapy with light Thai massage
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 66
Study: 21844075

Group type: EXPERIMENTAL
Intervention: RenalGuard System with hydration using saline and N-acetylcysteine
Number of subjects: 292

Group type: COMPARATOR
Intervention: Sodium bicarbonate solution and N-acetylcysteine (control group)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: RenalGuard System
Number of subjects: 292
Study: 19852790

Group type: EXPERIMENTAL
Intervention: DMSA (one round, 3 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DMSA (seven rounds)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 17909950

Group type: EXPERIMENTAL
Intervention: Interdisciplinary work rehabilitation (IWR) program
Number of subjects: 71
Study: 12706319

Group type: EXPERIMENTAL
Intervention: 50 mg acarbose t.i.d. for 6 weeks, followed by 100 mg acarbose t.i.d. for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10690137

Group type: EXPERIMENTAL
Intervention: Variable pitch pulse oximeter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed pitch pulse oximeter
Number of subjects: 30
Study: 8942116

Group type: EXPERIMENTAL
Intervention: Visual mnemonic device using a distinctive plastic plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1754607

Group type: EXPERIMENTAL
Intervention: Piracetam (4.8 g daily for 6 weeks)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 101
Study: 7073918

Group type: EXPERIMENTAL
Intervention: Trendelenberg position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study: 30731334

Group type: EXPERIMENTAL
Intervention: Cardiotocography with fetal ECG ST-segment analysis (ECG-F group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cardiotocography alone (CTG group)
Number of subjects: 200
Study: 28420417

Group type: EXPERIMENTAL
Intervention: Early image group (received future self-image at recruitment)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Delayed image group (received future self-image after 8 weeks)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Second image group (received an additional future self-image at 16 weeks)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No additional image group (did not receive an additional future self-image at 16 weeks)
Number of subjects: 145
Study: 26147316

Group type: EXPERIMENTAL
Intervention: Modified Story Memory Technique (mSMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23732552

Group type: EXPERIMENTAL
Intervention: Jerte Valley cherry‐based product (JVCP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Kool‐Aid®)
Number of subjects: 30
Study: 21970852

Group type: EXPERIMENTAL
Intervention: Erlotinib (oral antiepidermal growth factor receptor tyrosine kinase inhibitor)
Number of subjects: 1942